Intravenous Artesunate and Malaria
Information source: University of Khartoum
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria
Intervention: artesunate (Drug); Quinine (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Khartoum
Summary
Intravenous artesunate is egual to quinine in the treatment of severe malaria
Clinical Details
Official title: Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: clearance of the parasite and fever
Detailed description:
Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form
of fever clearance time and parasite clearance time
Eligibility
Minimum age: 1 Year.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
severe P. falciparum malaria-
Exclusion Criteria:
mixed infection Pregnant women -
Locations and Contacts
Kassala, Kassala 249, Sudan; Recruiting Abzinab A Ali, MD, Phone: +249911259199, Ext: 122, Email: ishagadamm@yahoo.com Tajeldien A Abdulla, MD, Principal Investigator
Additional Information
Related publications: Eltahir HG, Omer AA, Mohamed AA, Adam I. Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2010 Oct;104(10):684-6. doi: 10.1016/j.trstmh.2010.05.009. Epub 2010 Jun 17.
Starting date: March 2013
Last updated: March 4, 2013
|